Materiały źródłowe

• #1 Epidemiology of pyoderma gangrenosum: Results from an Italian prospective multicentre study

  https://pmc.ncbi.nlm.nih.gov/articles/PMC7949684/

  Pyoderma gangrenosum (PG) is described as a rare disease: the worldwide incidence is estimated to be around 3 to 10 cases per million population per year. […] In an Italian population of roughly 8 million inhabitants of 7 provinces, we found an incidence of 5.17 new cases per million population per year. […] To the best of our knowledge, there is only 1 population-based study that assesses the epidemiology of PG and 1 prospective single-centre study that does not give hints about the incidence of PG. […] In our observational multicentre study, we collected a total of 64 cases, of which 40 were new cases, in a 13-month period, with a mean age of 58.3 years and equal gender distribution. […] Thus, unlike our predictions before the study, we confirm the worldwide incidence of PG. […] The data we gathered of 64 patients during the 13-month study period are in accordance with those described in the literature: the incidence of PG was of 5.17 new cases per million population per year. […] Prospective multicentre studies are the only reliable way to collect a critical number of patients to better understand the real epidemiology of PG and its features, being a disease still underestimated and frequently misdiagnosed.

• #2 Pyoderma gangrenosum – a review | Orphanet Journal of Rare Diseases | Full Text

  https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-2-19

  Accurate epidemiological data on PG are missing. The peak of incidence occurs between the ages of 20 to 50 years with women being more often affected than men. […] The general incidence has been estimated to be between 3 and 10 per million per year. […] Cases in infants and adolescents account for only 4% of PG. PG in elderly people has occasionally been reported.

• #3 Pyoderma gangrenosum: Pathogenesis, clinical features, and diagnosis – UpToDate

  https://www.uptodate.com/contents/pyoderma-gangrenosum-pathogenesis-clinical-features-and-diagnosis

  Pyoderma gangrenosum (PG) is a rare disorder with an estimated incidence of 3 to 10 cases per million people per year. […] Individuals of any age may be affected, including children. […] PG most commonly develops in young and middle-aged adults, with an average age of onset between 40 and 60 years. […] Between the sexes, women are more frequently affected.

• #4 Pyoderma gangrenosum: Pathogenesis, clinical features, and diagnosis – UpToDate

  https://www.uptodate.com/contents/pyoderma-gangrenosum-pathogenesis-clinical-features-and-diagnosis/print

  PG is a rare disorder with an estimated incidence of 3 to 10 cases per million people per year. […] Individuals of any age may be affected, including children. […] PG most commonly develops in young and middle-aged adults, with an average age of onset between 40 and 60 years. […] Between the sexes, women are more frequently affected.

• #5 Pyoderma Gangrenosum: A Report of 15 Cases and Review of the Literature | Actas Dermo-Sifiliográficas

  https://www.actasdermo.org/es-pyoderma-gangrenosum-a-report-15-articulo-S1578219012000637

  Pyoderma gangrenosum is a condition that is included among the neutrophilic dermatoses. Given its low incidence, few studies have addressed its epidemiology or treatment. […] The incidence of pyoderma gangrenosum in our reference population is 3.26 cases per million inhabitants per year. […] Only 20% of cases (3 patients) were referred first to the dermatology department, indicating that dermatology plays a secondary role in the care of patients with PG. This may be because almost half of the patients included in our study had gastrointestinal disease, with PG coinciding with periods of worsening of the systemic disease. […] In our study, we observed a female to male ratio of 1.14 to 1. PG usually appears in patients aged between 30 and 50 years. […] The most common systemic disease in our patients was inflammatory bowel disease (40%; 5 cases of ulcerative colitis and 1 case of Crohn disease), and in most of those (4 cases with ulcerative colitis), PG developed during a disease flare.

• #6 Pyoderma Gangrenosum: A Report of 15 Cases and Review of the Literature | Actas Dermo-Sifiliográficas

  https://www.actasdermo.org/en-pyoderma-gangrenosum-a-report-15-articulo-S1578219012000637

  Pyoderma gangrenosum is a condition that is included among the neutrophilic dermatoses. Given its low incidence, few studies have addressed its epidemiology or treatment. […] The incidence of pyoderma gangrenosum in our reference population is 3.26 cases per million inhabitants per year. […] Only 20% of cases (3 patients) were referred first to the dermatology department, indicating that dermatology plays a secondary role in the care of patients with PG. […] In between 50% and 70% of cases, PG is associated with systemic disease. […] The incidence of PG in our reference population is 3.26 cases per million inhabitants per year. […] According to our findings, age younger than 40 years appears to be related to an increase in the probability of having an associated systemic disease in patients with PG. […] Given the low incidence of PG, there are no studies available to support the development of a standard treatment algorithm.

• #7 The Pathophysiology and Treatment of Pyoderma Gangrenosum—Current Options and New Perspectives

  https://www.mdpi.com/1422-0067/25/4/2440

  Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis characterized by a painful, aseptic ulcer. […] The specific epidemiology of PG is difficult to estimate since only a few cross-sectional studies have been conducted so far. In a recent American study, the prevalence of PG was evaluated at 58 individuals with PG per 1 million adults. […] The United Kingdom research indicated an incidence rate of 0.63 per 100,000 person years. […] PG occurs mostly around the age of 50, with a higher prevalence and incidence among women than men. […] It has been reported that the mortality of patients with PG could be threefold higher than in the control group after adjustments for sex and age. […] There are also data indicating the negative influence of PG on quality of life.

• #8 Pyoderma Gangrenosum: Symptoms and Treatment | Doctor

  https://patient.info/doctor/pyoderma-gangrenosum-pro

  PG is uncommon. Incidence is estimated to be around 3-10 cases per million population per year worldwide. A UK study estimated incidence rate to be around 0.91 per 100,000 person-years. It may occur at any age, but the peak incidence is over the age of 50, with a slight female preponderance. […] A UK-based study found that people with PG had a three times higher risk of death than the general population.

• #9 Pyoderma Gangrenosum: Background, Epidemiology, Prognosis

  https://emedicine.medscape.com/article/1123821-overview

  Pyoderma gangrenosum occurs in about 1 in 100,000 persons each year in the United States. A Spanish study that examined hospital admissions for pyoderma gangrenosum as a percentage of total hospital admissions over the period 1999-2021 found that in 2021, pyoderma gangrenosum admissions accounted for 91.9 of every 1,000,000 admissions. […] All ages may be affected by the disease, but it predominantly occurs in the fourth and fifth decades of life. Children account for only 3-4% of the total number of cases. Nothing is clinically distinctive about pyoderma gangrenosum in children and adolescents, other than the age of the patients. Although this condition is known to affect both sexes, a slight female predominance may exist.

• #10 Pyoderma gangrenosum – Autoimmune Association

  https://autoimmune.org/disease-information/pyoderma-gangrenosum/

  Pyoderma gangrenosum is a rare, destructive inflammatory skin disease of which a painful nodule or pustule breaks down to form a progressively enlarging ulcer. […] Each year in the United States, pyoderma gangrenosum occurs in about 1 person per 100,000 people.

• #11 Prevalence estimates for pyoderma gangrenosum in the United States: An age- and sex-adjusted population analysis – PubMed

  https://pubmed.ncbi.nlm.nih.gov/31400451/

  The disease burden of pyoderma gangrenosum (PG) is poorly understood. […] To determine standardized overall and age-, sex-, and race-specific prevalence estimates for PG among adults in the United States. […] The age- and sex-standardized prevalence of PG among the study population was 0.0058%, or 5.8 PG cases (95% confidence interval [CI], 5.6-6.1) per 100,000 adults. Adjusted prevalence was nearly twice as high among women (7.1 cases [95% CI, 6.7-7.5] per 100,000) than men (4.4 cases [95% CI, 4.0-4.7] per 100,000). Patients between the ages of 70 and 79 years had the highest standardized prevalence (9.8 cases [95% CI, 8.8-10.9] per 100,000), with patients aged 50 years representing nearly 70% of all PG cases. Standardized prevalence was similar among white and African American patients. The female-to-male ratio of PG was 1.8 across all age groups. […] PG is a rare disease that most commonly affects women and those aged 50 years.

• #12 The Role of Ultra-High-Frequency Ultrasound in Pyoderma Gangrenosum: New Insights in Pathophysiology and Diagnosis

  https://www.mdpi.com/2075-4418/13/17/2802

  Pyoderma gangrenosum (PG) is a neutrophilic dermatosis of unknown etiology and uncertain epidemiology due to its challenging diagnosis. Its estimated prevalence is approximately 58 cases per million people, with an incidence of approximately 6 cases per million. […] The average age of onset is 59 years with a higher prevalence in women, even if some studies suggest that the higher incidence occurs between 20 and 50 years old, without gender differences. […] The mortality rate associated with PG ranges from 16% to 27%. […] Furthermore, approximately 50% of PG patients are affected by another immune disease, although some studies report a slightly lower frequency. Notably, PG is the second most common cutaneous manifestation of inflammatory bowel disease (IBD). […] The epidemiology of PG varies depending on the clinical phenotypes, which includes ulcerative, pustular, bullous and vegetative forms.

• #13 Pyoderma Gangrenosum (PG) Market Outlook and Forecast-Thelansis

  https://thelansis.com/reports/pyoderma-gangrenosum-pg-market-outlook-forecast/

  The prevalence of PG, standardized for age and sex, is 5.8 cases per 100,000 adults. Adjusted prevalence rates indicate a nearly two-fold higher occurrence in women (7.1 cases per 100,000) compared to men (4.4 cases per 100,000). […] The highest standardized prevalence is observed in individuals aged 70 to 79 (9.8 cases per 100,000), with patients aged 50 or older accounting for nearly 70% of all PG cases. […] KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. […] This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

• #14 Orphanet: Pyoderma gangrenosum

  https://www.orpha.net/en/disease/detail/48104

  The worldwide incidence of pyoderma gangrenosum (PG) is estimated to be between 3-10 cases per million people with an increased incidence in women. […] The exact prevalence of PG is unknown but has been estimated to be approximately 1 in 17,000 adults. It tends to affect middle-aged individuals (40-60 years).

• #15 Pyoderma gangrenosum: a review with special emphasis on Latin America literature | Anais Brasileiros de Dermatologia

  https://www.anaisdedermatologia.org.br/en-pyoderma-gangrenosum-review-with-special-articulo-S0365059619300686

  Pyoderma gangrenosum is considered a rare disease with an estimated prevalence of two to three cases per 100,000 people and an adjusted incidence rate of 0.63 per 100,000 person-years. Risk of death is three times higher than general controls. It tends to have a slight predominance for females. Differences in comorbid conditions and differential diagnoses to consider vary significantly depending on geographic regions and local disease prevalence. Reports from LA are scarce and mostly consist of case reports or case series. […] In LA, 118 studies were found from 1981 to 2018, with 232 cases of PG. Brazil was the country with the largest report of case-series, with 96 (41.4%) cases of PG. The next highest total was from Argentina, which has 69 (29.7%) reported cases of PG, followed by Chile and Mexico, which have a similar number of reported cases, with 21 (9.1%) and 17 (7.3%), respectively. […] Thus, the systematic review of PG case-series from LA helped to elucidate the main associated conditions.

• #16 SciELO Brazil – Pyoderma gangrenosum: a review with special emphasis on Latin America literature^, Pyoderma gangrenosum: a review with special emphasis on Latin America literature^,

  https://www.scielo.br/j/abd/a/vwtb5kb76QcBvst7mwjrttH/?lang=en

  Pyoderma gangrenosum is considered a rare disease with an estimated prevalence of two to three cases per 100,000 people and an adjusted incidence rate of 0.63 per 100,000 person-years. Risk of death is three times higher than general controls. Differences in comorbid conditions and differential diagnoses to consider vary significantly depending on geographic regions and local disease prevalence. Reports from Latin America are scarce and mostly consist of case reports or case series. […] In Latin America, 118 studies were found from 1981 to 2018, with 232 cases of pyoderma gangrenosum. Brazil was the country with the largest report of case-series, with 96 (41.4%) cases of pyoderma gangrenosum. The next highest total was from Argentina, which has 69 (29.7%) reported cases of pyoderma gangrenosum, followed by Chile and Mexico, which have a similar number of reported cases, with 21 (9.1%) and 17 (7.3%), respectively. […] The systematic review found that there was a high prevalence of pyoderma gangrenosum cases associated with comorbidities. Overall, 149 (64.5%) and 37 (16%) of the patients included in the analysis had pyoderma gangrenosum associated with a condition or surgery, respectively.

• #17 Pyoderma gangrenosum | Radiology Reference Article | Radiopaedia.org

  https://radiopaedia.org/articles/pyoderma-gangrenosum?lang=us/1000

  It is most common in people aged 20 to 50 years old and is rarely found in children or the elderly. […] Approximately 50% of patients will have an underlying systemic disorder including: ulcerative colitis (10-15%), Crohn disease (10-15%), hepatitis C, seronegative arthropathy, spondylitis, lymphoproliferative diseases.

• #18 Top Published Expert Doctors for Pyoderma Gangrenosum

  https://findexpertmd.com/d/Pyoderma_Gangrenosum?physician=physician

  638 top medical experts on Pyoderma Gangrenosum across 62 countries and 34 U.S. states, including 532 MDs (Physicians). This is based on an objective analysis of their Scientific Publications, Clinical Trials, Medicare, and NIH Grants. […] The majority of cases are in people between 40 and 60 years old. […] Clinical Trials ClinicalTrials.gov: at least 23 including 1 Active, 7 Completed, 3 Recruiting.

• #19 Clinicopathological features and prognosis of pyoderma gangrenosum in Korea: A single centre, retrospective, observational study over 20 years – Indian Journal of Dermatology, Venereology and Leprology

  https://ijdvl.com/clinicopathological-features-and-prognosis-of-pyoderma-gangrenosum-in-korea-a-single-center-retrospective-observational-study-over-20-years/

  Pyoderma gangrenosum appears to have ethnic differences. Underlying haematologic disorders and bullous subtype have a worse prognosis. However, the type of histopathology did not correlate with the clinical outcome of pyoderma gangrenosum. […] The estimated incidence of pyoderma gangrenosum in western countries is 310 patients per million population per year. […] There has been a paucity of reports on Asian cases of pyoderma gangrenosum as well, despite its possible ethnic differences. […] The presence of haematologic disorders was associated with a frequent recurrence and poor survival rate, consistent with the findings of previous studies. […] The first line of the treatment of pyoderma gangrenosum is an empirical systemic steroid administration because of the lack of controlled studies to date.

• #20 SciELO Brazil – Pyoderma gangrenosum: a review with special emphasis on Latin America literature^, Pyoderma gangrenosum: a review with special emphasis on Latin America literature^,

  https://www.scielo.br/j/abd/a/vwtb5kb76QcBvst7mwjrttH/

  Pyoderma gangrenosum is considered a rare disease with an estimated prevalence of two to three cases per 100,000 people and an adjusted incidence rate of 0.63 per 100,000 person-years. Risk of death is three times higher than general controls. Differences in comorbid conditions and differential diagnoses to consider vary significantly depending on geographic regions and local disease prevalence. Reports from LA are scarce and mostly consist of case reports or case series. […] In LA, 118 studies were found from 1981 to 2018, with 232 cases of PG. Brazil was the country with the largest report of case-series, with 96 (41.4%) cases of PG. The next highest total was from Argentina, which has 69 (29.7%) reported cases of PG, followed by Chile and Mexico, which have a similar number of reported cases, with 21 (9.1%) and 17 (7.3%), respectively.

• #21 Pyoderma Gangrenosum – Epidemiology Forecast to 2032

  https://www.researchandmarkets.com/reports/5525897/pyoderma-gangrenosum-epidemiology-forecast-to?srsltid=AfmBOoqAjtTn8LU4b4z9sr0ajasDB4xCQkl9HZ9I1jsYvlhAK1S64yoX

  This „Pyoderma Gangrenosum – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Pyoderma Gangrenosum epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. […] The Pyoderma Gangrenosum epidemiology report gives a thorough understanding of the Pyoderma Gangrenosum by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. […] The Pyoderma Gangrenosum epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. […] The Pyoderma Gangrenosum epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032.

• #22 Pyoderma Gangrenosum – Market Insight, Epidemiology and Market Forecast – 2034

  https://www.researchandmarkets.com/reports/5524367/pyoderma-gangrenosum-market-insight?srsltid=AfmBOor5R6fQlMkiQnGL6UEEi292kIECyxM1ToBQ0kDNT15GvDVbu1U8

  The Pyoderma Gangrenosum epidemiology division provide insights about historical and current Pyoderma Gangrenosum patient pool and forecasted trend for every seven major countries. […] The disease epidemiology covered in the report provides historical as well as forecasted Pyoderma Gangrenosum epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034. […] The epidemiology segment also provides the Pyoderma Gangrenosum epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

• #23 Pyoderma Gangrenosum: Symptoms, Causes, and Treatment — DermNet

  https://dermnetnz.org/topics/pyoderma-gangrenosum

  Pyoderma gangrenosum is a rare disease that affects males and females of any age but is more common in those aged over 50 years. It frequently is associated with an internal disease or condition. Its known associations include: […] About half of those affected by pyoderma gangrenosum have none of the associated risk factors. […] IBD-associated pyoderma gangrenosum has the following characteristics: Pyoderma gangrenosum represents the second-most common cutaneous manifestation of IBD (13%). It is more commonly a complication of ulcerative colitis compared to Crohn disease. […] Pyoderma gangrenosum is diagnosed by its characteristic appearance and severe pain. The pathergy test is usually positive (a skin prick test causing a papule, pustule, or ulcer). […] The prognosis for pyoderma gangrenosum is unpredictable. About half of treated patients achieve wound healing on treatment with prednisone or ciclosporin within a year.

• #24 Pyoderma gangrenosum: challenges and solutions | CCID

  https://www.dovepress.com/pyoderma-gangrenosum-challenges-and-solutions-peer-reviewed-fulltext-article-CCID

  PG has been estimated to occur in three to ten individuals/million. However, it is difficult to determine the exact disease prevalence, as accurate epidemiological data are missing. PG is most commonly observed in young to middle-aged adults, with women being more affected. […] The diagnosis is commonly challenging and delayed, and misdiagnosis is also frequent, mostly by non-dermatologists who are less aware of this entity. […] PG can involve only the skin, but in more than half the cases it is associated with an underlying systemic disease, which can occur before, coincidently, or after the diagnosis. […] Once considered a pathognomonic feature of ulcerative colitis, PG is now known to occur in association with several other distinct diseases. The most common are arthritis (namely: seronegative arthritis, ankylosing spondylitis, and rheumatoid arthritis), Crohns disease, and myeloproliferative disorders or monoclonal gammopathy. […] The disease often shows a chronic relapsing course; therefore, long-term prognosis of PG is unpredictable, and the decision on the treatment duration can be difficult. Importantly, careful management of chronic underlying disorders is critical to prevent rebound flares.

• #25 SciELO Brazil – Pyoderma gangrenosum: a review with special emphasis on Latin America literature^, Pyoderma gangrenosum: a review with special emphasis on Latin America literature^,

  https://www.scielo.br/j/abd/a/vwtb5kb76QcBvst7mwjrttH/

  The systematic review found that there was a high prevalence of PG cases associated with comorbidities. Overall, 149 (64.5%) and 37 (16%) of the patients included in the analysis had PG associated to a condition or surgery, respectively. In the rest of PG patients, no other conditions or disease associations were reported. IBD was the most frequent conditions associated (53/149, 35.6%), then ulcerative colitis (UC) (32/149, 21.5%) and Crohn’s disease (10/149, 6.7%). Other inflammatory diseases were also frequent (54/149, 36.2%); among them, rheumatoid arthritis (RA) (17/149, 11.4%), antiphospholipid syndrome (APS) (15/149, 10.1%), systemic erythematous lupus (4/149, 2.7%), and Takayasu’s arteritis (4/149, 2.7%) were reported. Several malignances were reported in association with PG (19/149, 12.8%), in particular hematologic malignancies (14/149, 9.4%) and solid-organ malignancies (5/149, 3.4%). […] The most frequent form of PG is the ulcerative subtype, which is most commonly associated with IBD. An accurate diagnosis in LA is even more challenging, as the prevalence of cutaneous infections that mimic all forms of PG is higher compared to developed countries.

• #26 Clinicopathological features and prognosis of pyoderma gangrenosum in Korea: A single centre, retrospective, observational study over 20 years – Indian Journal of Dermatology, Venereology and Leprology

  https://ijdvl.com/clinicopathological-features-and-prognosis-of-pyoderma-gangrenosum-in-korea-a-single-center-retrospective-observational-study-over-20-years/

  Pyoderma gangrenosum is a rare autoinflammatory neutrophilic dermatosis that rapidly evolves. However, little is known about the clinicopathological features and prognosis of pyoderma gangrenosum. […] We aimed to document clinicopathologic and prognostic data of the patients with pyoderma gangrenosum. […] In this retrospective observational study, we reviewed case records of patients diagnosed with pyoderma gangrenosum between 1999-2019. […] Fifty-three patients were identified by reviewing medical records for skin biopsy; of these, 37 were men and 16 were women. Mean age at onset was 43.3 18.5 years. The most frequently affected area was the lower extremities (60.4%), followed by the head and neck (17.0%). The most common subtype was ulcerative (47.2%), followed by bullous (22.6%). 30 cases had underlying diseases and the most common were malignancy (24.5%), followed by inflammatory bowel diseases (18.9%). The proportion of cases with history of trauma were significantly higher in post-operative type (100%) as compared to the bullous type (8.3%). Histologic features of granulation tissue were frequently found in post-operative type (66.7%) and bullous type (58.3%). Granulomas were predominantly found in bullous type (58.3%). Age 60 years appeared to be significantly associated with multiple lesions. Partial-to-complete remission was observed in 40 cases (75.5%). Nine (17.0%) cases experienced recurrence with a median progression-free period of six months (interquartile range of 3.0-9.0 months). Cases with underlying hematologic disorders and the bullous subtype were significantly associated with early recurrence.

• #27 Clinicopathological features and prognosis of pyoderma gangrenosum in Korea: A single centre, retrospective, observational study over 20 years – Indian Journal of Dermatology, Venereology and Leprology

  https://ijdvl.com/clinicopathological-features-and-prognosis-of-pyoderma-gangrenosum-in-korea-a-single-center-retrospective-observational-study-over-20-years/

  In this study, the use of systemic glucocorticoid or oral immunosuppressant had been chosen for more severe or extensive pyoderma gangrenosum cases, whereas topical agents such as steroid and calcineurin inhibitors had been considered for mild cases with shallow ulcers. […] Nine (17.0%) of 53 cases experienced recurrence; however, this frequency was lower than the recurrence rates of 24-46% reported in a previous study. […] Because the pyoderma gangrenosum groups with haematologic disorders, bullous type and an initial skin lesion of 4 cm in size showed a significantly short progression-free period, prompt and early administrations of immunosuppressive strategies are recommended in these cases. […] Pyoderma gangrenosum appeared to have ethnic differences in clinical manifestations such as the frequency of each subtype, associated diseases and prognostic risk factors. Underlying haematologic disorders and bullous subtype have a prognostic significance.

• #28 Pyoderma Gangrenosum is Associated with Low Socioeconomic Status: A Single-Site, Cross-Sectional Study

  https://clinmedjournals.org/articles/ijdrt/journal-of-dermatology-research-and-therapy-ijdrt-7-105.php?jid=ijdrt

  Pyoderma gangrenosum (PG) is an uncommon, non-infectious, inflammatory skin disorder affecting individuals of all ages. […] Understanding the SES of a patient population is vital to providing a personalized approach for disease management that addresses potential barriers including transportation, work flexibility, cost of medications, and wound care. […] Approximately 33% of patients with PG had very low SES, defined by SES index scores in the lowest two gross income deciles, compared to 20% among the general healthcare system patient population. […] Patients with PG have lower SES and are more likely to have government insurance or no insurance than other medical and dermatology patient populations. […] Individuals with PG were more likely to have Medicaid insurance or be uninsured and have a very low SES, defined by education, unemployment, property value, household income, rent, and poverty level compared to the general medical patient population in this study. […] A greater portion of patients with PG have lower SES than the general patient population. SES is a proxy for access to care and individuals with a lower SES are less likely to receive proper treatment or early diagnoses.

• #29 The challenges of managing patients with pyoderma gangrenosum: three case reports :: Cambridge Media Journals

  https://journals.cambridgemedia.com.au/wpr/volume-24-no-1/challenges-managing-patients-pyoderma-gangrenosum-three-case-reports

  Epidemiology data for the condition is based predominantly on case reports, case series and cohort studies, mostly in patients with inflammatory bowel disease. A rare condition, the incidence is estimated at three to 10 cases per million per year. Based on a large population-based cohort study the incidence in the UK is estimated at six per million per year. PG generally affects people between the ages of 20 and 50 years; it has also been reported in approximately 4% of children. Data regarding gender is contradictory. According to some there is a higher incidence in females, although others have reported no gender preference.

• #30 Top Published Expert Doctors for Pyoderma Gangrenosum

  https://findexpertmd.com/d/Pyoderma_Gangrenosum

  638 top medical experts on Pyoderma Gangrenosum across 62 countries and 34 U.S. states, including 532 MDs (Physicians). This is based on an objective analysis of their Scientific Publications, Clinical Trials, Medicare, and NIH Grants. […] The majority of cases are in people between 40 and 60 years old. Its etiology is unknown. […] Clinical Trials ClinicalTrials.gov: at least 23 including 1 Active, 7 Completed, 3 Recruiting.

• #31 The Role of Ultra-High-Frequency Ultrasound in Pyoderma Gangrenosum: New Insights in Pathophysiology and Diagnosis

  https://www.mdpi.com/2075-4418/13/17/2802

  The ulcerative phenotype is the most prevalent form, primarily affecting the lower limbs. […] PG is frequently associated with IBD, rheumatoid arthritis (RA), seronegative arthritis, monoclonal gammopathy, and hematological malignancies. […] Because of the chronic and relapsing course of PG, finding early biomarkers of this transition could be useful in terms of therapeutic decision making and response monitoring. […] Currently, PG remains a diagnosis of exclusion as there are no validated and specific clinical, instrumental, or serological markers. […] The substantial therapeutic differences between inflammatory and non-inflammatory phases require imaging tools and quantitative parameters to guide and support treatment choice. […] The distinction between the inflammatory and non-inflammatory phases of PG is essential for the choice of the correct therapeutic approach, either topical or systemic.

• #32 Pyoderma Gangrenosum – Epidemiology Forecast to 2032

  https://www.researchandmarkets.com/reports/5525897/pyoderma-gangrenosum-epidemiology-forecast-to?srsltid=AfmBOoqAjtTn8LU4b4z9sr0ajasDB4xCQkl9HZ9I1jsYvlhAK1S64yoX

  The Pyoderma Gangrenosum epidemiology covered in the report provides historical as well as forecasted Pyoderma Gangrenosum epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032. […] The report provides insight into the historical and forecasted patient pool of Pyoderma Gangrenosum in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan. […] The report assesses the disease risk and burden and highlights the unmet needs of Pyoderma Gangrenosum. […] The Pyoderma Gangrenosum Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies.

• #33 Pyoderma Gangrenosum Market Size, Forecast Report 2035

  https://www.imarcgroup.com/pyoderma-gangrenosum-market

  The pyoderma gangrenosum market has been comprehensively analyzed in IMARC’s new report titled „Pyoderma Gangrenosum Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035”. […] The increasing prevalence of immune system dysregulation or dysfunction, causing the body’s defense mechanisms to attack healthy tissues, is primarily driving the pyoderma gangrenosum market. […] IMARC Group’s new report provides an exhaustive analysis of the pyoderma gangrenosum market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc.

• #34 Pyoderma Gangrenosum Market Size, Forecast Report 2035

  https://www.imarcgroup.com/pyoderma-gangrenosum-market

  According to the report, the United States has the largest patient pool for pyoderma gangrenosum and also represents the largest market for its treatment. […] What is the number of incident cases (2019-2035) of pyoderma gangrenosum across the seven major markets? […] What is the size of the pyoderma gangrenosum patient pool (2019-2024) across the seven major markets? […] What would be the forecasted patient pool (2025-2035) across the seven major markets? […] What are the key factors driving the epidemiological trend of pyoderma gangrenosum? […] What will be the growth rate of patients across the seven major markets?

• #35 The Role of Ultra-High-Frequency Ultrasound in Pyoderma Gangrenosum: New Insights in Pathophysiology and Diagnosis

  https://www.mdpi.com/2075-4418/13/17/2802

  To date, the assessment of the inflammatory phase in PG is performed exclusively by clinical examination of the lesions: an intensified pain experienced by the patient, an increase in the number of lesions, and the presence of lilac ring are clinical parameters suggestive of a transition to the inflammatory phase. […] It is therefore a current challenge to identify early and more objective biomarkers, detectable even before clinical parameters, suggestive of the transition from the inflammatory phase to the non-inflammatory one, to guide therapeutic choice. […] The results obtained by our investigation revealed some UHFUS differences between the inflammatory and non-inflammatory phases. […] These UHFUS findings could be explained by the increased dermal oedema in T0, which resulted in surrounding connective tissue compression and morphological blood vessels changes.

• #36 The Role of Ultra-High-Frequency Ultrasound in Pyoderma Gangrenosum: New Insights in Pathophysiology and Diagnosis

  https://www.mdpi.com/2075-4418/13/17/2802

  The UHFUS characteristics found in T0 decreased in number and density in T1, but did not disappear. […] This result could be explained by two theories. First, the permanence of some UHFUS features could be suggestive of a new potential inflammatory flair, thus justifying the need for immunomodulatory maintenance therapy even in the non-inflammatory phase. […] Moreover, the presence of similar UHFUS findings between the pustular and ulcerative phenotypes in T0, suggested the idea, not yet confirmed in the literature, that the pustular phenotype was an early stage of the ulcerative one.

Zobacz więcej